Daratumumab, lenalidomide and dexamethasone are clinically beneficial for frail patients with multiple myeloma
Combination therapy of daratumumab, lenalidomide, and dexamethasone (D-Rd) led to clinical response in frail patients with newly diagnosed multiple myeloma. A team, led by Aurore Perrot, MD, PhD, Center Hospitalier Universitaire de Toulouse, Department of Hematology, evaluated patient-reported outcomes in frail patients in data presented at the 2022 annual meeting of the American Society of …